{"data":{"id":1308,"lang":"en","title":"New Drug Baxdrostat Cuts Blood Pressure by 10 mmHg in Patients Who Don't Respond to Standard Treatment","summary":"Phase 3 trial shows baxdrostat lowers blood pressure by nearly 10 mmHg in patients resistant to standard treatment, with 40% reaching target levels.","category":"science","category_label":"Science","published_at":"2026-04-06T09:02:25Z","updated_at":"2026-04-06T09:02:25Z","url":"https://techtools.cz/tools/news/article/1308-new-drug-baxdrostat-cuts-blood-pressure-by-10-mmhg-in-patients-who-don-t","api_url":"https://techtools.cz/news-api/v1/articles/1308?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/1308.md?lang=en","image_url":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/shutterstock_752759212.jpg","word_count":168,"reading_time_minutes":1,"sources":[{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2507109","domain":"nejm.org"},{"url":"https://www.escardio.org/The-ESC/Press-Office/Press-releases/Blood-pressure-reductions-with-baxdrostat-in-patients-with-uncontrolled-or-resistant-hypertension","domain":"escardio.org"},{"url":"https://www.pharmaceutical-technology.com/analyst-comment/acc-2026-baxdrostat-lowers-bp-in-uncontrolled-hypertension/","domain":"pharmaceutical-technology.com"}],"translation":{"lang":"cs","id":1362,"title":"Nový lék baxdrostat snižuje krevní tlak o 10 mmHg u pacientů, kterým nezabírá standardní léčba","url":"https://techtools.cz/tools/news/clanek/1362-novy-lek-baxdrostat-snizuje-krevni-tlak-o-10-mmhg-u-pacientu-kterym-nezabira","api_url":"https://techtools.cz/news-api/v1/articles/1362?lang=cs"},"content":"A Phase 3 trial published in the New England Journal of Medicine shows baxdrostat, a selective aldosterone synthase inhibitor developed by AstraZeneca, significantly lowers blood pressure in patients with resistant and uncontrolled hypertension. The BaxHTN trial enrolled 796 patients across 214 clinics worldwide, with 73% suffering from resistant hypertension despite taking three or more medications.\n\nAfter 12 weeks, patients on the 2 mg dose saw placebo-adjusted systolic blood pressure drop by 9.8 mmHg, with 40% reaching the target level below 130 mmHg — compared to just 18.7% on placebo. Ambulatory monitoring showed even larger reductions of 16.9 mmHg over 24 hours. Safety was generally favorable, with confirmed high potassium levels occurring in about 1% of patients.\n\nProfessor Bryan Williams from University College London, who presented the results, called baxdrostat \"one of the first therapies\" to selectively block aldosterone production. A meta-analysis of three trials presented at the American College of Cardiology 2026 conference confirmed the consistent blood pressure-lowering effect. The FDA has already accepted AstraZeneca's application for priority review."}}